PL2004168T3 - Stabilna doustna kompozycja farmaceutyczna zawierająca agonistów receptorów hormonów tarczycy - Google Patents

Stabilna doustna kompozycja farmaceutyczna zawierająca agonistów receptorów hormonów tarczycy

Info

Publication number
PL2004168T3
PL2004168T3 PL07723634T PL07723634T PL2004168T3 PL 2004168 T3 PL2004168 T3 PL 2004168T3 PL 07723634 T PL07723634 T PL 07723634T PL 07723634 T PL07723634 T PL 07723634T PL 2004168 T3 PL2004168 T3 PL 2004168T3
Authority
PL
Poland
Prior art keywords
hormone receptor
thyroid hormone
pharmaceutical composition
composition containing
receptor agonists
Prior art date
Application number
PL07723634T
Other languages
English (en)
Inventor
Neeraj Garg
Venkatramana M Rao
Rajesh B Gandhi
William N Washburn
Konrad Koehler
Johan Malm
Original Assignee
Karobio Ab
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karobio Ab, Bristol Myers Squibb Co filed Critical Karobio Ab
Publication of PL2004168T3 publication Critical patent/PL2004168T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL07723634T 2006-03-28 2007-03-27 Stabilna doustna kompozycja farmaceutyczna zawierająca agonistów receptorów hormonów tarczycy PL2004168T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0606212.9A GB0606212D0 (en) 2006-03-28 2006-03-28 Pharmaceutical compositions
PCT/EP2007/002688 WO2007110226A1 (en) 2006-03-28 2007-03-27 Stable oral pharmaceutical composition containing thyroid hormone receptor agonists
EP07723634A EP2004168B1 (en) 2006-03-28 2007-03-27 Stable oral pharmaceutical composition containing thyroid hormone receptor agonists

Publications (1)

Publication Number Publication Date
PL2004168T3 true PL2004168T3 (pl) 2012-01-31

Family

ID=36424743

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07723634T PL2004168T3 (pl) 2006-03-28 2007-03-27 Stabilna doustna kompozycja farmaceutyczna zawierająca agonistów receptorów hormonów tarczycy

Country Status (20)

Country Link
US (1) US20090220598A1 (pl)
EP (1) EP2004168B1 (pl)
JP (1) JP2009531359A (pl)
KR (1) KR20090013770A (pl)
CN (1) CN101426488B (pl)
AT (1) ATE518534T1 (pl)
AU (1) AU2007229626A1 (pl)
BR (1) BRPI0709688A2 (pl)
CA (1) CA2642880A1 (pl)
DK (1) DK2004168T3 (pl)
ES (1) ES2369674T3 (pl)
GB (1) GB0606212D0 (pl)
MX (1) MX2008012385A (pl)
NO (1) NO20083605L (pl)
NZ (1) NZ570689A (pl)
PL (1) PL2004168T3 (pl)
PT (1) PT2004168E (pl)
RU (1) RU2450810C2 (pl)
WO (1) WO2007110226A1 (pl)
ZA (1) ZA200807597B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0724478D0 (en) * 2007-12-14 2008-01-30 Karobio Ab Pharmaceutical compositions
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2609910A1 (en) * 2011-12-30 2013-07-03 Deva Holding Anonim Sirketi Formulations of eprotirome
CN106727453B (zh) * 2017-01-13 2019-04-26 鲁东大学 一种化合物在制备治疗甲状腺机能减退症药物中的应用
EP3894383A1 (en) * 2018-12-12 2021-10-20 Autobahn Therapeutics, Inc. Novel thyromimetics
CA3130371A1 (en) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Novel thyromimetics
IT201900006923A1 (it) * 2019-05-16 2020-11-16 International Soc For Drug Development S R L Nuovi tiromimetici con uno scaffold bifenilmetano e loro uso
CN115279359A (zh) * 2019-11-29 2022-11-01 速通医疗公司 新型拟甲状腺素药
EP4168384A4 (en) 2020-06-17 2024-07-10 Autobahn Therapeutics, Inc. THYROMIMETICS
EP4167986A4 (en) 2020-06-17 2024-11-20 Autobahn Therapeutics, Inc. THYROMIMETICS
AU2022271304A1 (en) 2021-05-06 2023-11-23 Autobahn Therapeutics, Inc. Fatty acid amide hydrolase (faah) cleavable prodrugs of thyromimetics and combination with peripherally restricted faah inhibitors
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
AU2024408289A1 (en) 2023-12-22 2026-08-06 Tangram Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5883294A (en) * 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
US5849337A (en) * 1997-06-27 1998-12-15 Gusty Winds Corporation Method of enhancing magnesium absorption and prevention of atherosclerosis
PL201790B1 (pl) * 2000-02-17 2009-05-29 Bristol Myers Squibb Co Anilinopochodny ligand dla receptora tarczycy, jego zastosowanie i kompozycja farmaceutyczna
WO2002032427A1 (en) * 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
WO2003070217A1 (en) * 2002-02-15 2003-08-28 King Pharmaceuticals, Inc. Levothyroxine compositions and methods
ITMI20011401A1 (it) * 2001-07-02 2003-01-02 Altergon Sa Formulazioni farmaceutiche per ormoni tiroidei
MXPA04011312A (es) * 2002-05-17 2005-02-14 Esperion Therapeutics Inc Metodo para el tratamiento de desordenes dislipidemicos.
GB0215978D0 (en) * 2002-07-10 2002-08-21 Karobio Ab Novel compounds
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
TW200504021A (en) * 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7670624B2 (en) * 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system

Also Published As

Publication number Publication date
CN101426488B (zh) 2012-03-21
NO20083605L (no) 2008-11-07
EP2004168A1 (en) 2008-12-24
JP2009531359A (ja) 2009-09-03
RU2008142524A (ru) 2010-05-10
HK1126404A1 (en) 2009-09-04
EP2004168B1 (en) 2011-08-03
ES2369674T3 (es) 2011-12-02
KR20090013770A (ko) 2009-02-05
NZ570689A (en) 2011-12-22
WO2007110226A1 (en) 2007-10-04
MX2008012385A (es) 2009-03-02
BRPI0709688A2 (pt) 2011-07-19
DK2004168T3 (da) 2011-10-31
PT2004168E (pt) 2011-10-24
US20090220598A1 (en) 2009-09-03
CA2642880A1 (en) 2007-10-04
AU2007229626A1 (en) 2007-10-04
GB0606212D0 (en) 2006-05-10
ZA200807597B (en) 2009-06-24
ATE518534T1 (de) 2011-08-15
CN101426488A (zh) 2009-05-06
RU2450810C2 (ru) 2012-05-20

Similar Documents

Publication Publication Date Title
ZA200807597B (en) Stable oral pharmaceutical composition containing thyroid hormone receptor agonists
BRPI0821128A2 (pt) Composição farmacêuticas
MX2010007150A (es) Formulaciones del factor de von-willebrand recombinante.
MX2009012000A (es) Derivados de pirazol heteroarilo sustituidos utiles para el tratamiento de trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis.
MY148496A (en) Dpp iv inhibitor formulations
MY148634A (en) Pyridazinone derivatives
AU2009215514A9 (en) Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
WO2010048275A3 (en) Lyophilized recombinant vwf formulations
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
JO2831B1 (en) Quinclidine carbonate derivatives and pharmaceutical compounds
UA98804C2 (ru) Катехоламиновые производные и фармацевтическая композиция на их основе
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
SI1539114T1 (sl) Filmska obloga za tablete in kaplete
TW200738627A (en) Trialkylsilyl-indoles
WO2009117401A8 (en) Compositions for site-specific delivery of imatinib and methods of use
TN2009000510A1 (en) Extended release formulation of nevirapine
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
TW200640857A (en) Substituted pyrroles and imidazoles, compositions containing same, manufacturing process therefor and use thereof
MX2010006215A (es) Derivados de piperazina y su uso como moduladores del receptor de leptina.
MX2010006216A (es) Nuevos compuestos iii.
GEP20135819B (en) 3-(2,2,2-trimethylhydrazinium) propionate dihydrate composition of local administration
GB0615105D0 (en) Novel compounds
MX2012000113A (es) Compuestos alcoxi-carbonil-amino-alquinil-adenosina y derivados de los mismos como agonistas a2ar.
TW200706173A (en) Oral composition comprising carbamylating agent
WO2007143506A3 (en) Substituted benzimidazole thiophene benzyl ether compounds